A clinical study of Stalaris for the treatment of lung diseases

Trial Profile

A clinical study of Stalaris for the treatment of lung diseases

Planning
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs ATYR-1923 (Primary)
  • Indications Lung disorders
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 New trial record
    • 16 Mar 2017 According to an aTyr Pharma media release, the company anticipates to start this study in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top